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ARTICLE
Targeting stromal remodeling and cancer stem cell
plasticity overcomes chemoresistance in triple
negative breast cancer
Aurélie S. Cazet 1,2,3, Mun N. Hui1,2,4,5, Benjamin L. Elsworth6, Sunny Z. Wu1,2,3, Daniel Roden1,2,3,
Chia-Ling Chan1,2, Joanna N. Skhinas1,2, Raphaël Collot1,2, Jessica Yang1,2, Kate Harvey1,2, M. Zahied Johan7,8,
Caroline Cooper9, Radhika Nair10, David Herrmann 1,2,3, Andrea McFarland1,2, Niantao Deng1,2,3,
Manuel Ruiz-Borrego11, Federico Rojo12, José M. Trigo13, Susana Bezares14, Rosalía Caballero14, Elgene Lim1,2,3,15,
Paul Timpson1,2,3, Sandra O’Toole1,2,5, D. Neil Watkins1,2,3,15, Thomas R. Cox 1,2,3, Michael S. Samuel 7,8,
Miguel Martín16 & Alexander Swarbrick1,2,3
The cellular and molecular basis of stromal cell recruitment, activation and crosstalk in
carcinomas is poorly understood, limiting the development of targeted anti-stromal therapies.
In mouse models of triple negative breast cancer (TNBC), Hedgehog ligand produced by
neoplastic cells reprograms cancer-associated ﬁbroblasts (CAFs) to provide a supportive
niche for the acquisition of a chemo-resistant, cancer stem cell (CSC) phenotype via FGF5
expression and production of ﬁbrillar collagen. Stromal treatment of patient-derived xeno-
grafts with smoothened inhibitors (SMOi) downregulates CSC markers expression and
sensitizes tumors to docetaxel, leading to markedly improved survival and reduced metastatic
burden. In the phase I clinical trial EDALINE, 3 of 12 patients with metastatic TNBC derived
clinical beneﬁt from combination therapy with the SMOi Sonidegib and docetaxel che-
motherapy, with one patient experiencing a complete response. These studies identify
Hedgehog signaling to CAFs as a novel mediator of CSC plasticity and an exciting new
therapeutic target in TNBC.
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Carcinogenesis draws many parallels with developmentalbiology. During development, dynamic interactionbetween stromal and epithelial cells drives patterning and
function. Cell fate speciﬁcation occurs through activation of
transcriptional cascades in response to extracellular signals from
developmental signaling pathways such as Hedgehog (Hh), Wnt,
Notch, BMP (bone morphogenetic proteins), and FGF (ﬁbroblast
growth factor)1,2. These pathways direct developmental processes
either by direct cell-to-cell contact or through secreted diffusible
factors (paracrine signaling). They can act individually or in
concert with each other. For example, the interaction between Hh
and FGF signaling pathways has been shown to mediate tracheal
and lung branching morphogenesis3. In mature, differentiated
tissues, these pathways are quiescent but may be reactivated to
drive repair and regeneration to maintain tissue homeostasis.
More speciﬁcally, the Hh developmental pathway is reactivated
in a subset of cancers. Binding of Hh ligand to its receptor Pat-
ched (PTCH) enables Smoothened (SMO)-mediated transloca-
tion of Gli1 into the cell nucleus to drive the transcription of Hh
target genes4. Mutations in Hh pathway components are onco-
genic drivers in “Gorlin’s-like” cancers such as medulloblastoma
and basal cell carcinoma where tumors rely on cell-autonomous
Hh signaling5. Small molecule inhibitors of SMO (SMOi), Vis-
modegib and Sonidegib, are well-tolerated and clinically approved
for the treatment of these lesions5. In contrast, many other solid
tumors, including breast cancer, predominantly exhibit ligand-
dependent pathway activation4–6. While Hh signaling is quiescent
in the adult mammary gland, Hh ligand expression is reactivated
in a subset of breast cancers, particularly the poor-prognosis
triple negative breast cancer (TNBC) subtype6. Thirty percent of
TNBCs exhibit paracrine Hh pathway signature, deﬁned by high
epithelial HH ligand expression in combination with high stromal
GLI1 expression, which is associated with a greater risk of
metastasis and breast cancer-speciﬁc death6.
Neoplastic cells co-opt components of the tumor micro-
environment (TME) to further their progression. The TME is a
complex ecosystem comprising a myriad of neoplastic and non-
malignant cells embedded in a glycoprotein-rich extracellular
matrix (ECM). Prominent cell types include the endothelium,
cells of the immune system and cancer-associated ﬁbroblasts
(CAFs). In addition to its role as a physical scaffold to support
tissue architecture, the ECM also functions as a signal transducer
between the different TME cell types7. The stiffness of the ECM
and the abundance of ﬁbrillar collagen immediately adjacent to
epithelial lesions provide mechanical signals that facilitate tumor
development and progression8,9. Not surprisingly, the TME has
emerged as a major determinant of cancer phenotype. In breast
cancer, stromal metagenes, in particular those associated with
ECM remodeling, strongly predict prognosis and response to
chemotherapy10,11.
While it is now apparent that Hh signals in a paracrine manner
in animal models of TNBC6 and in isolated cancer stem cells
(CSCs)12, a detailed study of the dynamic crosstalk within the
TME is required to make clinical progress in integrating anti-
stromal therapies into breast cancer treatment. Progress has been
impeded by the ﬁeld’s limited understanding of the mechanisms
underlying tumor−stromal interactions, a limited repertoire of
well-tolerated agents to target the TME, and an absence of pre-
dictive biomarkers for response to TME-directed therapies. In
this study, we showed that CAFs are the primary stromal cells
that respond to Hh ligand stimulation. Activated CAFs in turn
provide a conducive environment for neoplastic cells to acquire a
chemo-resistant stem-like phenotype. SMOi treatment sensitized
tumors to docetaxel chemotherapy in mouse models and in
patients from the EDALINE Phase I clinical trial, resulting in
reduced metastatic burden and improved survival.
Results
Hh-tumors are enriched for a reversible CSC-like phenotype.
To investigate the mechanistic basis for Hh-dependent tumor
growth and metastasis in TNBC, we used the murine M6 allograft
model of low grade TNBC, in which transgenic Hh expression
drives invasion, metastasis, and high-grade morphology6 (M6-
Hh; Supplementary Fig. 1a). Treatment with the SMO inhibitor
(SMOi) GDC-0449 (Vismodegib; 100 mg/kg/bid) slowed tumor
growth, reduced metastatic burden and improved overall animal
survival of M6-Hh tumors (Supplementary Fig. 1b–d). M6-Ctrl
and M6-Hh monoculture cell viability were similar between
vehicle and SMOi treatment and the expression of canonical Hh
target genes Ptch, Gli1, and Hhip were downregulated in vivo but
not in vitro, consistent with a paracrine requirement for Hh
signaling as previously reported6,12,13 (Supplementary Fig. 1e–g).
The effects of SMO inhibition on tumor growth and gene
expression were not observed in control tumors lacking Hh
expression (M6-Ctrl) or in benign adult mouse mammary gland
(Supplementary Fig. 1b, g, h), reﬂecting on-target drug activities.
Similar results were observed with the SMOi NVP-LDE-225
(Sonidegib; 80 mg/kg/day; Supplementary Fig. 1i, j).
To examine the transcriptional changes induced by Hh
pathway activation in detail, we dissociated and analyzed freshly
ﬂow cytometry-sorted stromal and epithelial fractions of M6-Ctrl
and M6-Hh tumors ± SMOi using RNA-Sequencing (RNA-Seq)
(Fig. 1a). Differential gene expression analysis conﬁrmed effective
cellular fractionation, with Hh transgene expression restricted to
the epithelial cell population while Hh target genes Ptch, Gli1, and
Hhip expression were induced solely in the stromal fraction of
M6-Hh tumors (Supplementary Data 1).
In the epithelial compartment, 67 genes were differentially
expressed (>2-fold change, P < 0.001), with 60 upregulated and 7
downregulated genes in the neoplastic M6-Hh cells in compar-
ison to M6-Ctrl or M6-Hh cells treated with SMOi. Transcrip-
tional changes were robust and highly statistically signiﬁcant
(Fig. 1b). Hh expression in M6 cancer cells resulted in increased
expression of stemness genes14 including Peg3 (>11-fold), Igfbp4
(>7-fold), and Thy1 (>4-fold), which were downregulated
following SMO inhibition (Fig. 1b).
Gene set enrichment analysis (GSEA) and gene ontology (GO)
analysis of the puriﬁed epithelial fraction highlighted enrichment
for genes speciﬁcally and almost exclusively associated with
mammary stemness and invasion, consistent with the morpholo-
gically undifferentiated phenotype previously observed in Hh-
overexpressing tumors6 (Fig. 1c, d and Supplementary Data 1). To
examine the CSC phenotype in greater detail, epithelial cells were
proﬁled by ﬂow cytometry. M6-Hh tumors had a higher
proportion of CD61hi cells, previously shown to be a marker of
mouse mammary CSCs15, within the EpCAM+CD24hiCD29+
cancer cell population (55.3% in M6-Hh tumors vs. 36.4% in M6-
Ctrl tumors; Fig. 1e). M6-Hh tumors also had elevated expression
of the stemness markers Id3, Gpc3, Thy1, Sox10, and Krt6,
validating the RNA-Seq data (Fig. 1b, f). Following transplantation
of low numbers of sorted primary M6-Hh and M6-Ctrl cells into
naive recipients, tumors were detectable earlier, formed at a higher
frequency and survival was shorter in the M6-Hh group (Fig. 1g,
h). Limiting dilution assays16 were used to quantitate the impact
of Hh signaling on tumor-initiating capacity. M6-Ctrl and M6-Hh
tumor cells were isolated by FACS and transplanted at various
dilutions. M6-Hh cells had signiﬁcantly higher tumor-initiating
capacity (1 in 435) compared with M6-Ctrl cells (1 in 1088;
Fig. 1i). Importantly, the proliferation and expression of CSC
markers were indistinguishable between M6-Ctrl and M6-Hh cells
in monoculture, indicating that Hh expression in M6 cells does
not regulate CSC properties in a cell-autonomous manner
(Supplementary Fig. 1e).
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Immunohistochemical detection of the mammary progenitor
marker cytokeratin 6 (CK6; product of the Krt6 gene)17 localized
cells with a stem/progenitor signature speciﬁcally to the tumor
−stromal interface (Fig. 1j). SMO inhibition reduced the
expression of Id3, Gpc3, Thy1, Sox10, and Krt6 and signiﬁcantly
reduced the number of cells positive for CK6 and the mitotic
marker phospho-Histone H3 at the tumor−stromal interface
(Fig. 1f, j). These data demonstrate that paracrine Hh signaling
results in the induction of a reversible stem-like phenotype
preferentially at the tumor−stromal interface.
Hh-activated CAFs markedly remodel the ECM. RNA-Seq
analysis of the stromal fraction revealed 185 genes that were dif-
ferentially expressed (>2-fold, P < 0.001), with 146 upregulated
and 39 downregulated genes in the stroma of M6-Hh tumors
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compared to M6-Ctrl and M6-Hh tumor+ SMOi (Supplementary
Data 1). A number of genes were markedly upregulated by Hh
signaling, in particular the growth factor gene Fgf5 at more than
290-fold, St8Sia2 (>40-fold) and Tspan11 (>4-fold; Fig. 2a). The
large majority of gene expression changes in Hh-activated stroma
returned to baseline following treatment with SMOi (Fig. 2a and
Supplementary Data 1), suggesting that the stromal transcriptional
changes are SMO-dependent and reversible.
Comparative GO and GSEA analysis revealed that the stromal
fraction of M6-Hh tumors are highly enriched for genes encoding
ECM processes (Fig. 2b, c), suggesting that a major inﬂuence of
paracrine Hh activation on the tumor stroma is related to ECM
production and remodeling18. Genes highly enriched in this set
included collagens (Col2a1, Col3a1, Col4a1, Col9a1, Col11a1),
ECM remodeling metallopeptidases (Mmp3, Mmp13, Mmp15,
Adamts3, Adamts18), ECM glycoproteins (St8sia2, Rspo3, Lama5,
Edil3, Thbs4) and cell adhesion molecules (Cldn3, Cldn7, Cldn1,
Cdh2, Cdh15) (Fig. 2c). Interestingly, these ECM gene expression
changes were not a consequence of changes in stromal cellular
composition due to Hh pathway activation or long-term SMO
inhibition. Immunohistochemical analysis did not reveal any
difference between M6-Ctrl and M6-Hh tumors in terms of CAF,
endothelial and innate immune cell abundance, regardless of
treatment with SMOi (Supplementary Fig. 2a). This ﬁnding was
conﬁrmed using whole tumor qRT-PCR and ﬂow cytometry
analysis (Supplementary Fig. 2b, c).
To determine the prognostic value of the Hh-activated stromal
gene signature (HSGS), we examined its impact on overall
survival using The Cancer Genome Atlas (TCGA) breast invasive
carcinoma cohort19. The HSGS was not predictive of patient
outcome in the unstratiﬁed patient cohort (Fig. 2d) but was
associated with signiﬁcantly lower patient overall survival
uniquely in the basal breast cancer subtype, where Hh ligand is
most frequently overexpressed6 (Hazard ratio= 9.7 (1.9−48.2); P
< 0.001; Fig. 2d).
Accumulating evidence suggests that CAFs contribute to tumor
growth upon Hh ligand activation12,20. However, the stroma of
M6 tumors is composed of multiple cell types, any of which may
be responsible for Hh-dependent gene expression changes. We
used a single-cell RNA-sequencing (scRNA-Seq) approach to
determine the cell population/s that respond to paracrine Hh
signaling. The microﬂuidic 10× Chromium system was used to
comprehensively proﬁle gene expression at cellular resolution in
thousands of cells isolated from freshly dissociated M6-Ctrl and
M6-Hh tumors ± SMOi. In total, we compared 6064 FACS-
isolated cells from M6-Ctrl tumors, 6200 cells from M6-Hh
tumors, and 2686 single cells from M6-Hh tumor treated with
SMOi.
As shown in Fig. 3a, unsupervised clustering analysis of 14,950
cells revealed populations of myeloid, neoplastic, endothelial,
CAF and natural killer cells within the breast TME (Fig. 3a).
Importantly, the upregulation of canonical Hh target genes Gli1,
Ptch1, Ptch2, and Hhip and ECM genes such as Col4a1, Tspan11,
St8sia2, and Tnfaip6 was observed exclusively in the CAF
population of M6-Hh tumors (Fig. 3a), and not in the other
stromal cell types. More speciﬁcally, the ECM signature detected
in the stroma of Hh-expressing tumors via “bulk” RNA-Seq was
driven by CAF gene expression (Figs. 2b, c, 3b). scRNA-Seq also
conﬁrmed the lack of autocrine Hh pathway activation within the
neoplastic cells (Fig. 3a). Treatment with SMOi almost completely
reversed the Hh-dependent gene expression changes observed in
CAFs without affecting gene expression in the other stromal cell
types (Fig. 3a; Supplementary Fig. 2d and Supplementary Data 2),
highlighting the on-target activity of SMOi at the single-cell level.
Coculture of primary CAFs with M6-Hh cells was sufﬁcient to
induce the expression of the Hh target genes Ptch2, Gli1, and
Hhip in CAFs (Supplementary Fig. 3a, b) with concomitant
upregulation of CSC markers Id3, Sox10, Itgb3, and Krt6b in M6-
Hh cells (Supplementary Fig. 3a, c). Importantly, this stromal-
epithelial malignant crosstalk was blocked by SMOi (Fig. 3a,
Supplementary Fig. 3b, c). These data allow us to conclude that
Hh signaling occurs solely in a paracrine manner in this murine
model of TNBC and that CAFs are the therapeutic target of SMOi
in TNBC.
Hh-dependent collagen remodeling promotes cancer stemness.
Bulk and scRNA-Seq data suggested that stromal Hh-signaling
drives collagen remodeling in the local ECM (Figs. 2b, c, 3),
which is known to associate with breast cancer progression21. We
employed second harmonic generation (SHG) microscopy, a
sensitive label-free method for quantifying ﬁbrillar collagen
density and orientation in tissues22. SHG analysis revealed a ~3-
fold increase in ﬁbrillar collagen density at the tumor−stromal
interface of Hh-expressing tumors (Fig. 4a), but not in the tumor
center (data not shown). The increase in collagen abundance was
conﬁrmed by chromogenic staining using Picrosirius red
(Fig. 4b). Further detailed analyses of the distribution and
orientation of collagen ﬁbers as described by Mayorca-Guiliani
et al.23 and by Gray level co-occurrence matrix (GLCM) analy-
sis24 revealed changes in texture and crosslinking of the ECM
with linearization of collagen ﬁbers adjacent to epithelial lesions
Fig. 1Malignant epithelial cells with increased self-renewal properties are located adjacent to the stroma of Hh-expressing cancers. a Scheme depicting the
puriﬁcation of epithelial and mixed stromal populations from disaggregated M6 murine tumor models. b Expression of genes signiﬁcantly downregulated
(blue) or upregulated (red) by RNA-Seq analysis (cut-off log2 (Fold Change)≥ 2; vertical lines) in the epithelium of M6-Hh tumors compared to the
epithelium of M6-Ctrl or M6-Hh tumors treated with the SMOi, GDC-0449 (100mg/kg/bid), plotted against FDR values (horizontal lines indicate −log10
(FDR) > 2). Each symbol represents the transcriptome from ﬁve biological replicates per treatment group. c GSEA analysis reveals signiﬁcant enrichment
for genes encoding stemness and invasion in M6-Hh primary cells (FDR q value < 0.05). d Heat map showing relative CSC genes expression in the
epithelium of M6-Hh tumors compared to M6-Ctrl and M6-Hh tumors+ SMOi. Data show normalized row Z-score (n= 5 biological replicates for each
treatment group). e Representative FACS dot plots showing the expression of CSC markers CD61 and CD29 within the EpCAM+/GFP+/CD24+ population
of M6-Ctrl and M6-Hh tumors (n= 3 biological replicates per group). f Relative expression of key stemness genes in M6-Ctrl and M6-Hh whole tumors ±
SMOi (100mg/kg/bid). n= 3 biological replicates per treatment group; statistical signiﬁcance was determined using unpaired two-tailed Student’s t test
with equal s.d. g Kaplan−Meier and h tumor penetrance curves of mice injected with 250 primary M6-Ctrl (blue) or M6-Hh cells (violet); n= 10 biological
replicates. Six tumors from the M6-Hh and two tumors from the M6-Ctrl models were detectable, respectively. Statistical signiﬁcance was determined
using log-rank test. i Primary M6-Ctrl and M6-Hh tumor cells were isolated by FACS and transplanted at various dilutions into recipient mice. Limiting
dilution analysis demonstrating higher in vivo tumor-forming capacity in M6-Hh cells compared to M6-Ctrl cells. n= 10 mice per condition.
j Representative images and quantiﬁcation of CK6-progenitor and phospho-Histone H3-positive cancer cells at the tumor−stromal interface of M6 tumor
models. Scale bars: 100 μm for CK6 and 200 μm for phospho-Histone H3. n= 3 biological replicates per treatment group. Statistical signiﬁcance was
determined using unpaired two-tailed Student’s t test; *P < 0.05; **P < 0.01. Bars represent mean ± s.e.m.
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in M6-Hh tumors, a hallmark of breast tumor growth and
invasiveness8,23 (Fig. 4a). These features were ameliorated in M6-
Hh tumors treated with SMOi (Fig. 4a), demonstrating an
ongoing dependency on SMO activation.
Sites of collagen deposition and crosslinking at the stromal
−epithelial interface were also associated with increased epithelial
phosphorylation and activation of focal adhesion kinase (FAK), a
key signaling intermediate downstream of integrin receptors
(Fig. 4c; Supplementary Fig. 4a). E-cadherin was used to mark
the epithelial compartment (Fig. 4c, d; Supplementary Fig. 4).
Increased phospho-FAK (pFAK) and CK6 expressions were ob-
served to occur in the same regions of the M6-Hh tumors
(Fig. 4d), linking ﬁbrillar collagen content to FAK signaling
and the acquisition of a stem-like phenotype in the neoplastic
cells. Importantly, mechano-signaling and cancer stemness
occurred primarily in dense collagen regions and were
not observed in the core of M6-Hh tumors (Supplementary
Fig. 4a, b).
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To directly assess the sufﬁciency of collagen mechano-signaling
to promote stemness, the clonogenic potential of M6-Ctrl and
M6-Hh cells was assessed using three-dimensional cultures
encapsulated within Alginate-Collagen I Inter-Penetrating Net-
work (IPN) hydrogels. Alginates are widely used in bioengineer-
ing approaches as scaffolds25 and previous work has shown the
successful application of IPNs for the study of ﬁbroblast biology26
and the role of ECM biomechanics in the induction of malignant
phenotypes in mammary epithelium27. In our experiments,
biomechanical properties were precisely controlled through
regulation of alginate gelation. The enrichment for ﬁbrillar
collagen in this in vitro model allowed the uncoupling of 3D
environmental biomechanics from biochemistry, recapitulating
the features of stromal collagen matrix deposition observed in
Hh-expressing models. Increased content and presence of highly
bundled ﬁbrillar collagen signiﬁcantly increased the clonogenic
capacity of M6 cells, a functional surrogate for CSC activity,
independently of Hh ligand expression (Fig. 4e). Furthermore,
increasing collagen I abundance also increased expression of the
stem cell markers Id3, Itgb3 (CD61) and Krt6 (CK6) (Fig. 4f).
These data demonstrate that Hh-dependent stromal ECM
remodeling is sufﬁcient to foster a CSC phenotype.
Paracrine Hh-FGF5 axis also contributes to CSC plasticity. To
identify additional mechanisms by which stromal signaling
a
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promotes the acquisition of a CSC phenotype, we turned our
attention to Fgf5, which was strongly upregulated in Hh-activated
stroma compared to controls (Fig. 2a, c and Supplementary
Data 1 and 2). qRT-PCR analysis of whole tumors conﬁrmed
~60-fold upregulation of Fgf5 mRNA in M6-Hh tumors, which
was reversed upon SMOi treatment (Fig. 5a). Notably, a sole
subset of Hh-activated CAFs exhibited robust Fgf5 expression at
single-cell resolution (P= 9.16×10−12), reﬂecting the close spatial
localization of these CAFs with M6-Hh cells (Fig. 5b). Fgf5 was
not expressed by any of the other cell populations (Fig. 5b).
Immunohistochemical analysis of phospho-FGFR revealed potent
receptor activation in epithelial cells adjacent to M6-Hh tumor
stroma, which was reversed upon SMOi treatment (Fig. 5c). To
explore the role of FGF5 in the acquisition of the CSC phenotype,
M6-Ctrl cells were treated with recombinant FGF5 protein
in vitro and proliferation, stem cell marker expression and
sphere-forming capacity were evaluated. FGF5 treatment led to
an increase in proliferation under serum and growth factor
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deprivation (Supplementary Fig. 5a). Importantly, the stemness
markers Id3 and Sox10 were also robustly upregulated (Fig. 5d)
and primary and secondary sphere-forming capacity increased by
~3-fold (Fig. 5e and Supplementary Fig. 5b), suggesting a speciﬁc
effect of FGF5 signaling on stemness.
To test whether the induction of sphere-forming capacity by
FGF5 treatment was epigenetically stable or plastic, we tested the
impact of addition or removal of FGF5 to primary and secondary
sphere cultures. Increased sphere formation in response to FGF5
was observed in secondary cultures regardless of whether those
cells were pre-treated with FGF5 during primary cultures (Fig. 5e
and Supplementary Fig. 5b). Furthermore, removal of recombi-
nant FGF5 decreased secondary sphere formation to levels
comparable to those of cells never treated with FGF5 ligand
(Fig. 5e and Supplementary Fig. 5b). Consistent with this result,
treatment of spheres with a small molecule inhibitor of FGFR
signaling (NVP-BGJ398) prevented FGF5-mediated tumorsphere
formation in primary or secondary cultures (Supplementary
Fig. 5c). These results demonstrate that stromal-derived FGF5
is sufﬁcient to promote reversible transition to a CSC phenotype,
rather than through the expansion of a subpopulation of CSC.
The CSC phenotype is associated with resistance to cytotoxic
chemotherapy in TNBC28. To test whether the FGF-dependent
increase in CSC alters the sensitivity of TNBC cells to chemotherapy,
the efﬁcacy of docetaxel was evaluated in M6 cell lines in vitro.
Monocultures of M6-Hh cells did not display differential sensitivity
to docetaxel when compared to M6-Ctrl cells as expected
(Supplementary Fig. 5d). However, stimulation of M6-Ctrl and
M6-Hh models with recombinant FGF5 ligand rescued these cells
from docetaxel cytotoxicity (Fig. 5f). The FGFR inhibitor NVP-BGJ
398 abrogated drug resistance conferred by FGF5 (Fig. 5f). Similar
results were observed in the human MDA-MB-231 cell line model
of TNBC (Supplementary Fig. 5e). This result suggests that FGF5,
released by Hh-activated CAFs, may create a “chemo-resistant
niche” at the tumor−stromal interface of TNBC. It also suggests that
targeting both tumor and stromal compartments with chemother-
apeutic regimen and SMOi, respectively, may be an effectively
therapeutic strategy.
SMOi-combined therapy improves preclinical TNBC out-
comes. To directly test these ﬁndings in more clinically relevant
models, we turned our analysis to xenograft models of human
TNBC. All three patient-derived xenograft (PDX) models tested
were Hh ligand-positive as was the MDA-MB-231 cell line model
(Supplementary Fig. 6a). We found convincing evidence of
exclusive stromal-restricted Hh signaling and sensitivity to SMOi,
using species-speciﬁc RT-PCR (Supplementary Fig. 6b, c). In
addition, in vitro treatment of MDA-MB-231 cells with SMOi did
not alter Hh target gene expression or proliferation (Supple-
mentary Fig. 6d, e), consistent with the absence of SMO
expression by these cells. The HCI-002 and MDA-MB-231
models were used for further studies, as they are well-accepted
models of TNBC29.
Analyses of the ECM in HCI-002 xenografts by SHG and
picrosirius red staining revealed abundant ﬁbrillar collagen
exclusively at the tumor−stromal interface (Fig. 6a, b). The
collagen ﬁbers were highly linearized and densely packed as
depicted by orientation and GLCM analyses (Fig. 6a). Areas of
high ﬁbrillar collagen density were also associated with
concomitant FAK phosphorylation and expression of the human
CSC marker ALDH1 in the epithelial compartment, as high-
lighted by co-staining experiments (Fig. 6c). As observed in the
transgenic model, collagen density and orientation, FAK
phosphorylation and CSC marker expression were reduced
following SMO inhibition (Fig. 6a–c).
Based on these observations we predicted that SMOi would
sensitize tumors to cytotoxic chemotherapy. HCI-002 PDX and
MDA-MB-231 xenografts were then treated with SMOi ±
docetaxel (Fig. 6d–f). Compared with vehicle treatment, either
SMOi or docetaxel monotherapy slowed tumor growth and
extended mice survival (Fig. 6d, f). However, the most robust and
durable therapeutic effect occurred with combined therapy
(Fig. 6d, f). Interestingly, the proportion of mice with metastatic
disease at ethical endpoint (based on primary tumor size) was
doubled in the docetaxel treated group, an observation previously
made with paclitaxel in TNBC mouse models30 (Fig. 6e).
Combination therapy reduced the frequency of mice with
metastatic disease to below that seen in the vehicle control
group, despite these mice being alive much longer compared
to those in the other treatment groups. Similar therapeutic beneﬁt
was observed in MDA-MB-231 tumor-bearing mice treated with
combination therapy in terms of tumor growth, overall survival,
and histological changes (Supplementary Fig. 7a–d).
We then examined the impact of stromal Hh pathway
inhibition on the histology of the tumor epithelial and stromal
compartments. The proportion and number of stromal cells in
the HCI-002 PDX model were unaffected by long-term SMOi
and/or chemotherapy treatments (data not shown). SMOi had
no inhibitory effect on the proliferation of human cancer cells
across a range of doses (Supplementary Fig. 7e). Even in the
context of docetaxel chemotherapy, Hh signaling was still
stromally restricted (Supplementary Fig. 7f, g), arguing that
SMOi does not sensitize cells to docetaxel via a cell-autonomous
mechanism.
Fig. 4 High ﬁbrillar collagen content resulting from Hh pathway activation promotes mechano-signaling and breast cancer stemness. a–d Concomitant
expression analysis of collagen content and organization, integrin/focal adhesion activation and CSC-like characteristics at the tumor−stromal interface of
M6 tumor models ± SMOi (100mg/kg/bid; n= 3 biological replicates). a Representative multiphoton SHG imaging (scale bars: 100 μm) and quantitative
analysis of collagen abundance. Statistical signiﬁcance was determined using unpaired two-tailed Student’s t test with equal s.d. Corresponding graphs
comparing ﬁber orientation (top right panel) and quantifying GLCM (bottom right panel). Unpaired two-tailed nonparametric Mann–Whitney U test was
used for determining statistical signiﬁcance across distributions. For GLCM analysis, statistical signiﬁcance was determined using unpaired two-tailed
Student’s t test with equal s.d. b Collagen I and III deposition detected and quantiﬁed by picrosirius red staining. Scale bars, 200 μm. Statistical signiﬁcance
was determined using unpaired two-tailed Student’s t test with equal s.d. c Representative immunoﬂuorescence images and quantiﬁcation of phospho-FAK
and d CK6 expression. Scale bars, 100 μm. Statistical signiﬁcance was determined using Kruskal−Wallis test. e M6-Ctrl and M6-Hh single cells were
embedded and grown for 12 days in 3D Alginate IPNs containing increasing concentrations of collagen. Quantiﬁcation of the number of colonies was
normalized to the mean colony count in 0% collagen IPNs. n= 3 biological replicates with at least six technical replicates per condition. Statistical
signiﬁcance was determined using unpaired two-tailed Student’s t test with equal s.d. Representative phase contrast images of M6 colonies on
polyacrylamide substrata after 12 days of culture. Scale bars: 100 μm. f Relative mRNA expression of the CSC markers Id3, Igtb3, and Krt6b in M6-Ctrl and
M6-Hh cells cultured within 3D alginate-collagen I IPNs. n= 3 biological replicates with six technical replicates per experiment. Statistical signiﬁcance was
determined using unpaired two-tailed Student’s t test with equal s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Bars represent mean ± s.e.m.
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Clinical evaluation in the phase I clinical trial EDALINE. The
promising preclinical study results led us to establish the EDA-
LINE (GEICAM/2012-12) phase I trial of docetaxel in combi-
nation with SMOi (NVP -LDE225, Sonidegib) to determine the
maximum tolerated dose (MTD) and the recommended phase II
dose (RP2D) of this combined therapy in patients with metastatic
TNBC. Twelve patients with prior standard of care chemotherapy
treatments with taxanes and/or anthracyclines were enrolled.
Detailed information on clinical trial design, patient and treat-
ment characteristics are described in Supplementary Tables 1 and
2 and on ClinicalTrials.gov (Identiﬁer: NCT02027376). Combi-
nation therapy was well-tolerated and the RP2D of Sonidegib 800
mg once daily in combination with Docetaxel 75 mg/m2 every
21 days was established. Clinical response was evaluated
according to standard clinical trial RECIST31 (Response Evalua-
tion Criteria in Solid Tumors) criteria version 1.1. One patient
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experienced a complete clinical response, deﬁned as the dis-
appearance of all target and non-target tumor lesions and the
absence of new tumor lesions. As shown in Fig. 7a, the 54-year-
old postmenopausal woman presented with metastatic disease in
the lungs (red and blue arrows). Following eight cycles of com-
bined therapy, the patient achieved complete clinical response,
evident by the complete resolution of all her lung metastases on
routine progress CT scan (Fig. 7a and Supplementary Tables 1
and 2). Two other patients experienced disease stabilization
(Supplementary Tables 1 and 2).
To assess if stromal Hh pathway activation determines clinical
response, we evaluated epithelial HH ligand and stromal GLI1
expression in treatment naïve surgical tissue by immunochem-
istry. Only ten patient tumor samples were evaluable. Three out
of ten tumors had high paracrine Hh Pathway Activation
Signature (HPAS), characterized by high epithelial HH in
combination with high stromal GLI1 expression (Fig. 7b and
Supplementary Table 1). Of these, two patients experienced a
clinical response whereas all patients with low HPAS expression
had progressive metastatic disease on the prescribed treatment
regimen (Supplementary Table 2). An additional patient
experienced clinical beneﬁt, but the status of Hh pathway
activation was unknown as her tumor sample was not available
for analysis (Supplementary Table 2).
Downstream analysis of the effect of paracrine Hh signaling
revealed moderate to high phospho-FGFR expression, high
collagen deposition and ﬁber linearization in treatment-naive
tumor specimens of the two responders with biopsy material
available (Fig. 7c). This correlated with elevated phospho-FAK
mechano-signaling and ALDH1-positive cells at the tumor
−stromal interface (Fig. 7c). In contrast, the non-responder
with high paracrine HPAS exhibited weak phospho-FGFR
expression, low collagen content and minimal/no evidence
of mechano-signaling and breast CSCs (Fig. 7c). While the
small number of patients warrants caution, these additional
tumor factors deserve further investigation in future clinical
trials as adjunct biomarkers of therapeutic response for patient
selection for anti-SMOi-based combination therapies in Hh-
expressing TNBC.
Discussion
In certain settings, CSCs are responsible for metastasis to distant
organs32–34 and are frequently enriched in residual tumors following
chemotherapy35–37, reﬂecting a role in therapeutic resistance. The
hierarchical model for CSC maintenance proposes that CSCs behave
like tissue-resident physiological stem cells, self-renewing, and
undergoing asymmetric divisions to generate differentiated
progeny38. However, evidence from cell culture models has chal-
lenged the hierarchical CSC model, by suggesting that cancer
cells can transition into a CSC state under speciﬁc culture condi-
tions38–40. In support of this notion, we now demonstrate that
stromal cues from Hh-activated CAFs, including FGF and ﬁbrillar
collagen-rich ECM, are capable of inducing and maintain a stem-
like phenotype in TNBC cells in vivo. By combining a murine gain-
of-function model, small molecule inhibitor studies in human
xenografts with powerful in vitro systems, we have demonstrated the
plastic characteristics of breast CSCs that can be successfully targeted
using anti-stromal therapies, reducing metastatic growth and sen-
sitizing to taxane chemotherapy.
Increased stromal collagen content correlates with stemness in
the epidermis, both in the cancer and homeostatic contexts41,42. It
also enhances CSC properties of breast cancer cells in vitro43.
However, the impact of ECM collagen content and matrix
mechanical properties on the biology of CSCs is not well deﬁned.
Our work provides new mechanistic insights, demonstrating that
increased collagen density and ﬁber linearity at the tumor
−stroma interface are associated with FAK activation and
increased CSC number, dependent upon Hh paracrine signaling.
Notably, we report a relationship between collagen abundance
and clonogenicity in vitro and in vivo. Suppressing collagen
production using SMO inhibitors was associated with decreased
CK6+ and ALDH1+ CSCs, respectively, in both murine and
human models of TNBC. Interestingly, recent data links mam-
mographic ﬁbrillar collagen density to breast cancer risk, raising
the possibility that breast cancer progenitors in these patients
may have expanded in response to a dense collagen matrix21,44,45.
The precise mechanism controlling ﬁbrillar collagen ECM
remodeling in Hh-expressing tumors remains undetermined.
Further mechanistic investigations are needed to determine if Hh
induces the ﬁbrillar collagen program in CAFs through direct
regulation of collagen gene promoters via Gli1 or indirect inter-
action with other transcription factors, as shown in bone
formation46.
FGF signaling has been shown to drive malignant processes
including stem cell self-renewal, multipotency, and therapeutic
resistance47–50. In metastatic breast cancer, resistance to antic-
ancer treatment is primarily due to FGFR gene ampliﬁcation51.
Here, we demonstrate a novel ligand-driven mechanism by which
FGFR activation mediates both breast cancer stemness and che-
moresistance, downstream of activation of the Hh signaling
pathway. Importantly, our ﬁndings suggest that CAF targeting
using small molecule inhibitors of SMO is sufﬁcient to prevent
FGF ligand signaling and may overcome resistance to che-
motherapies. Interestingly, FGF5 has been reported to be upre-
gulated in prostate CAFs relative to normal ﬁbroblasts52, where it
Fig 5 Hh-activated CAFs form a reversible, chemo-resistant CSC niche via FGF pathway activity. a RT-qPCR analysis of Fgf5 expression in M6 whole
tumors. n= 3 biological replicates per treatment group with three technical replicates per assay. Statistical signiﬁcance was determined using unpaired
two-tailed Student’s t test with equal s.d. b Expression of Fgf5 at single-cell resolution in M6 tumor models. Freshly isolated M6-Ctrl (blue), M6-Hh
(magenta), and M6-Hh tumors+ SMOi (100mg/kg/bid; violin dots) were captured using 10x Chromium technology. t-SNE plot represents the subcellular
clusters present in the breast TME of M6 tumors. A sole subset of Hh-activated CAFs exhibits robust expression of Fgf5 in M6-Hh tumors.
c Representative immunohistochemistry staining for phospho-FGFR on M6 tumors. Scale bars: 100 μm. Quantiﬁcation of phospho-FGFR-positive cancer
cells at the tumor−stromal interface. n= 4 biological replicates per treatment group; statistical signiﬁcance was determined using unpaired two-tailed
Student’s t test with equal s.d. d Relative mRNA expression of CSC markers Id3 and Sox10 in M6-Ctrl cells treated with DMSO (vehicle; blue) or
recombinant FGF5 (red) in vitro. n= 3 biological replicates with three technical replicates per experiment; statistical signiﬁcance was determined using
unpaired two-tailed Student’s t test. e Primary and secondary tumorsphere formation of M6-Ctrl cells treated with DMSO (vehicle; blue) or recombinant
FGF5 (red). Sphere Formation Efﬁciency (SFE) values in % are mean ± s.e.m.; n= 3 biological replicates with three technical replicates per tumorsphere
assay. Representative phase contrast micrographs of M6-Ctrl spheres upon recombinant FGF5 stimulation. Scale bars: 100 μm. f Cell viability of M6-Ctrl
and M6-Hh cells treated with indicated agents (n= 5 biological replicates with six technical replicates each). Statistical signiﬁcance was determined using
unpaired two-tailed Student’s t test with equal s.d.; *P < 0.05; **P < 0.01; ***P < 0.001. Bars represent mean ± s.e.m.
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is also a target of Hh-Gli signaling. Thus this axis may be
operational, and of therapeutic value, in tumor types beyond
TNBC.
Which effects of CAFs on cancer stemness are mediated by
direct cell−cell interactions, and which by secreted factors are still
unknown. Moreover, how FGFR activation and high FAK
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Fig. 6 Efﬁcacy of long-term SMOi-combined therapy in preclinical models. a–c Concomitant expression analysis of collagen content and organization,
integrin pathway activation and CSC-like characteristics at the tumor−stromal interface of the TNBC HCI-002 PDX model treated with vehicle (red) or the
SMO inhibitor NVP-LDE225 (80mg/kg/day; blue) (n= 5 biological replicates). a Representative imaging (scale bars: 100 μm) and quantitative analysis of
collagen abundance (left panel). Statistical signiﬁcance was determined using unpaired two-tailed Student’s t test with equal s.d. Corresponding graphs
comparing ﬁber orientation (middle) and quantifying GLCM analysis (right panel) in the vehicle and SMOi-treated models. Unpaired two-tailed
nonparametric Mann–Whitney U test was used for determining statistical signiﬁcance across distributions. b Collagen I and III deposition detected and
quantiﬁed by picrosirius red staining. Scale bars, 200 μm. Statistical signiﬁcance was determined using unpaired two-tailed Student’s t test with equal s.d.
c Representative immunoﬂuorescence images and quantiﬁcation of concomitant phospho-FAK (green) and the human CSC marker ALDH1 (red)
expression in the HCI-002 model. The white arrows illustrate examples of co-staining within the epithelial population. Scale bars, 100 μm. n= 3 biological
replicates. Statistical signiﬁcance was determined using Kruskal−Wallis test. d–f TNBC HCI-002 PDX model treated with vehicle (blue), SMO inhibitor
(NVP-LDE225; 80mg/kg/day; magenta), chemotherapy (docetaxel; 15 mg/kg/week; dark orange) or NVP-LDE225 (80mg/kg/day)+ docetaxel (15 mg/
kg/week; orange line) (n= 7 mice per treatment group). d Tumor growth curves. Statistical signiﬁcance was determined using unpaired Student’s t test.
e Percentage of mice with detectable metastases in the lung, liver, and axillary lymph node in each treatment group. Statistical signiﬁcance was determined
using the Fisher’s exact test. f Kaplan−Meier curves of mice overall survival of each treatment group. Statistical signiﬁcance was determined using Log-
rank test of NVP-LDE225+ docetaxel vs. docetaxel; *P < 0.05; ***P < 0.001; ****P < 0.0001. Bars on the graphs represent mean ± s.e.m.
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mechano-signaling lead to the establishment of a stem-like phe-
notype remains to be determined, but they are associated in vitro
and in vivo with upregulation of transcription factors previously
implicated in mammary physiological and CSCs, including ID3
and SOX1048,53. The mechanisms underlying Id3 and Sox10
transcription are unknown. Id3 may be induced through Erk-
EGR1 signaling, as observed in activated T cells, downstream of
both FAK and FGFR54. Our data also reveal the cooperative
activity of ECM remodeling and FGF signaling in driving
malignancy and drug resistance, recapitulating the interaction
seen between these pathways during development and wound
healing55.
Importantly, many elements of Hh paracrine signaling to CAFs
are active during embryonic development in mammals, though
have not previously been linked. Dhh is highly expressed in a
subset of epithelial cells of the mammary end bud, an invasive
and proliferative structure responsible for ductal elongation in the
developing mouse mammary gland56. Consistent with our
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observation in TNBC, stromal but not epithelial Hh signaling is
required for appropriate ductal morphogenesis57. A number of
FGF ligands are secreted by mammary stromal cells, and acti-
vation of epithelial FGFR1/2 is required for mammary ductal
elongation and stem cell activity58,59. In addition, mammary
stromal ﬁbroblasts secrete and remodel ECM components
including collagens60. Similar to our results in neoplastic cells,
increased collagen density and mechano-signaling via FAK is
sufﬁcient to inhibit mammary epithelial cell differentiation and
increased clonogenic potential60. Thus the paracrine Hh signaling
we observe in TNBC most likely represents the dysregulation and
chronic activation of a process that is important for normal
mammary ductal morphogenesis.
Using high-throughput single-cell RNA-sequencing, we
demonstrate that CAFs are the only stromal cell type responding
to Hh ligand, and that SMO inhibitors act “on-target” to reverse
CAF gene expression changes induced by Hh signaling. Surpris-
ingly, long-term (up to 3 months) daily treatment with SMOi did
not alter the stromal cell composition of mammary tumors. This
result contrasts markedly to that recently observed in pancreatic,
colon and bladder cancer models, where chronic SMO inhibition
was associated with marked changes in stromal cellular compo-
sition and shorter survival for mice receiving long-term SMOi
treatment61–63. The basis for this difference is not known, but
may be explained by the divergent epigenomics contexts of these
cancer types, resulting in the evolution of distinct TMEs9.
Alternately, differences in the origin or phenotype of CAFs64 in
these endodermally derived tumors vs. ectodermally derived
mammary carcinomas may be relevant.
The beneﬁt from therapeutic targeting of CAFs is twofold.
Firstly, we and others have provided evidence for the crucial role
of CAFs in supporting CSC self-renewal and resistance to che-
motherapy65–67. Therefore, targeting the CAF population and the
subsequent abolition of the CAF−neoplastic cell interaction
represent a practical strategy to improve cancer outcomes. Sec-
ondly, unlike neoplastic cells, CAFs have not been reported to
exhibit genomic instability and are therefore less likely to acquire
resistance to therapy over time, making them good targets for
combination cancer therapies. Combined therapy with SMOi+
docetaxel was well-tolerated by mice and humans, and effective in
treating a proportion of women with metastatic disease who had
previously failed on taxane chemotherapy, including one patient
who experienced a complete response. While patient numbers are
small, these remarkable results provide the ﬁrst evidence to our
knowledge for clinical beneﬁt from a CAF-directed therapy.
Treatment response in patients correlated with high levels of
paracrine Hh signaling, FGFR activation and ﬁbrillar collagen
deposition, suggesting that the mechanism of action in patients
may be consistent with that in mouse models. Hh, FGFR or
collagen pathway activation may have value as predictive bio-
markers of response to SMOi. Thirty percent of TNBCs show
evidence of paracrine Hh pathway activity; SMO inhibitors could
then represent therapeutics of interest for a signiﬁcant number of
women. Whilst phase I clinical trials are not designed nor pow-
ered to assess therapeutic efﬁcacy, these data suggest an exciting
new therapeutic strategy for drug-resistant or metastatic TNBC
which should proceed to prospective assessment through Phase II
clinical trials.
Methods
Cell culture. M6 murine mammary carcinoma cells derived from the C3(1)/SV40
Tag mouse model (gift from J. Green, NIH)68 were cultured as previously
described6. The human triple negative breast cancer cell line MDA-MB-231 was
obtained from the American Type Cell Culture Collection (ATCC) and grown in
RPMI-1640 supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco®). All cell
lines were grown at 37 °C in a 5% CO2 incubator. Each cell line was characterized
by short tandem repeat analysis proﬁling using the PowerPlexR 18D System
(Promega) and tested for mycoplasma contamination (MycoAlertTM Mycoplasma
Detection kit, Lonza). SMOi GDC-0449 (S1082, Selleckchem) and NVP-LDE225
(Novartis, Australia) were dissolved in DMSO to stock concentration of 10 mM.
Docetaxel chemotherapy (McBeath, Australia) was diluted fresh (0.1 nM to 10 μM)
with cell culture media. Recombinant FGF-5 (237-F5-050, R&D) was reconstituted
at 10 μg/mL in PBS containing 1 μg/mL sodium heparin (H3149-50KU, Sigma-
Aldrich) and 0.1% bovine serum albumin (A9418-10G, Sigma-Aldrich). NVP-BGJ
398, a potent and selective FGFR inhibitor (S2183, Selleckchem) was used at a
concentration of 500 nM. All cell culture experiments involving SMOi (1 nM to
10 μM), NVP-BGJ 398 and chemotherapy (IC30) lasted 5 days and were performed
in the presence of FBS. For cell viability assays, treatment of M6 cells with
recombinant FGF-5 (150 ng/mL) in the absence of FBS lasted 5 days. Cell viability
assays were carried out in 96-well plates (Corning® Life Sciences) and were
determined by alamarBlue® reduction.
Tumor dissociation. M6 tumors were processed into single-cell suspensions before
limiting dilution assays, ﬂuorescence-activated cell sorting (FACS) or ﬂow cyto-
metry analysis. Tumor dissociation into single-cell suspension was carried out
using the MACS mouse Tissue Dissociation Kit (Miltenyi Biotec, Australia) in
gentleMACS C tubes on the gentleMACS Dissociator (Miltenyi Biotec) according
to the manufacturer’s recommended protocol. Brieﬂy, up to 1.5 g of tissue was
transferred into a gentleMACS C-Tube (Miltenyi Biotec) containing 2.35 mL of
RPMI 1640 solution with 1× Penicillin/Streptomycin (Gibco). 100 μL of enzyme D,
50 μL of enzyme R and 12.5 μL of enzyme A were then added and the sample was
processed by running the deﬁned gentleMACS program m_impTumor_02 on the
gentleMACS Dissociator. The sample was incubated for 40 min at 37 °C under
continuous agitation and then processed using the gentleMACS program
m_impTumour_03. The sample was resuspended in RPMI 1640 and ﬁltered
sequentially through 70 μm and 40 μm cell strainers (BD Falcon) and the resulting
single-cell suspension was centrifuged at 300 × g for 7 min. Cells were then
resuspended in 1× BD Pharm LyseTM lysing solution (555899, BD Biosciences) for
3 min at room temperature (RT) to lyse erythrocytes.
Flow cytometry and FACS isolation. Cell sorting and ﬂow cytometry experiments
were performed at the Garvan Institute Flow Cytometry Facility. Flow cytometry
was performed on a Becton Dickinson CantoII or LSRII SORP ﬂow cytometer
Fig. 7 Phase I clinical trial of docetaxel and SMO inhibitor, NVP-LDE225 (EDALINE) in patients with advanced TNBC. a Representative computed
tomography (CT) images from a patient with complete radiological response. The 54-year-old postmenopausal woman was diagnosed with recurrent
metastatic TNBC in the lungs with one measurable lesion on the right upper lobe (red arrow) and several nonmeasurable lesions (blue arrows).
Therapeutic response was evaluated according to RECIST criteria version 1.1. The remaining structure seen in the right upper lobe corresponds to the
azygos vein (violet arrow). b Representative HH and GLI1 immunostaining of treatment-naive tumor specimens from patients enrolled in the EDALINE trial.
The left panel is representative of patients with high HPAS (characterized by high epithelial HH ligand and high stromal GLI1 expression) while the right
panel represents low/intermediate epithelial HH and low stromal GLI1 expression. Scale bars: 100 μm. c Representative immunohistochemistry staining for
phospho-FGFR, collagen deposition depicted by SHG imaging and concomitant phospho-FAK and ALDH1 stem cell marker expression in treatment-naive
tumor specimens with high HPAS from the EDALINE trial. The left panel represents tissue derived from the patient who experienced a complete clinical
response, the middle is from the patient with stable disease and the right panel represents tissue from the patient with high HPAS who progressed on the
prescribed regimen. Scale bars: 100 μm. The white arrows illustrate examples of co-staining. d Graphical summary: Paracrine Hh signaling in TNBC drives a
reversible stem-like, chemo-resistant phenotype via FGF signaling and ECM remodeling. CAFs represent the primary cells of the breast TME that respond
to Hh ligand stimulation. Hh-activated CAFs enhance ECM collagen deposition and express FGF5 to establish a supportive niche for chemo-resistant
cancer stem cell maintenance. This study strongly highlights a novel rational approach targeting both the tumor cells and their surrounding signaling
support using SMO inhibitors to overcome chemoresistance in patients with TNBC
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using BD FACSDIVA software, and the results were analyzed using Flowjo soft-
ware (Tree Star Inc.). FACS experiments were performed on a FACS AriaII sorter
using the BD FACSorter software. Full details of each commercial antibody used
for ﬂow cytometry and immunochemistry are described in Supplementary Table 3.
Single-cell suspensions of primary M6 tumors were incubated with anti-CD16/
CD32 antibody (1:200, BD Biosciences) in FACS buffer (PBS containing salts, 2%
FBS, 2% Hepes) to block nonspeciﬁc antibody binding.
For the next generation sequencing experiment, single-cell suspensions were
then pelleted and resuspended in FACS buffer containing the anti-EpCAM-PerCP/
Cy5.5 (1:500, BioLegend®, Clone: G8.8) for 20 min on ice. Cells were then washed
twice in FACS buffer before being resuspended in FACS buffer containing DAPI
(1:1000; Invitrogen) to discriminate dead cells. Stromal cells identiﬁed as DAPI-/
GFP-/ EPCAM−and M6 cancer cells identiﬁed as DAPI−/ GFP+/EPCAM+ were
collected from at least ﬁve tumor specimens per treatment group.
For the isolation of M6-Ctrl or M6-Hh cells for limiting dilution assays, cells
were pelleted and resuspended in FACS buffer containing the following murine
lineage markers (Lin+): anti-CD45-biotin (1:100; BD PharmingenTM, Clone: 30-
F11); anti-CD31-biotin (1:40; BD PharmingenTM, Clone: 390), anti-TER119-biotin
(1:80; BD PharmingenTM, Clone: TER119), and anti-BP1-biotin (1:50; Affymetrix
eBiosciences, Clone: 6C3) for 20 min on ice. Cells were then pelleted and
resuspended in FACS buffer containing streptavidin-APC-CyTM7 (1:400; BD
PharmingenTM) and anti-EpCAM-PerCp/Cy5.5 (1:500, BioLegend®, Clone: G8.8),
and incubated for 20 min on ice. Cells were then washed twice in FACS buffer
before being resuspended in FACS buffer containing DAPI (1:1000; Invitrogen).
Live primary M6 neoplastic cells were sorted based on their GFP+/EpCAM+/Lin−
expression.
For the analysis of CSC properties, single-cell suspensions from M6 tumor
models were incubated with the combination of the following murine lineage
markers: anti-CD31-biotin (1:40), anti-CD45-biotin (1:100), anti-TER119-biotin
(1:80), and anti-BP1-biotin (1:50) for 20 min on ice. Cells were then pelleted and
resuspended in FACS buffer containing streptavidin-APC-CyTM7 (1:400) and the
following epithelial stem cell markers: anti-CD24-PE (1:500; BD PharmingenTM,
Clone: M1/69), anti-CD29-APC-Cy7 (1:100; BioLegend, Clone: HMβ1-1) and anti-
CD61-APC (1:50; ThermoFisher), and incubated for 20 min on ice. Cells were then
washed twice in FACS buffer before being resuspended in FACS buffer containing
DAPI (Invitrogen).
Coculture of primary cells. Primary M6 cells and CAFs derived from M6-Ctrl and
M6-Hh tumors, respectively, were selected by FACS using the following cell surface
markers: Epithelial cells: CD45−/CD31−/CD140a−/GP38−/EpCAM+/GFP+;
CAFs: CD45−/CD31−/CD140a+/GP38+/EpCAM−/GFP−. After tumor dissocia-
tion, single cells were pelleted and resuspended in FACS buffer containing the
following antibodies: anti-CD45-APC-eFluor®-780 (1:500; Affymetrix eBioscience,
Clone: 30-F11), anti-CD31-biotin (1:100; BD PharmingenTM, Clone: 390), anti-
CD140a-APC (1:100; BioLegend®, Clone: APA5), anti-Podoplanin-PE (1: 1,000,
BioLegend®, Clone: 8.1.1) for 20 min on ice. After two washes with PBS, cells were
then pelleted and resuspended in FACS buffer containing Brilliant Violet 421™
Streptavidin (1:400; BioLegend®), and incubated for 20 min on ice. Cells were then
washed twice in FACS buffer before being resuspended in FACS buffer containing
DAPI (Invitrogen) to discriminate dead cells. Different epithelial and CAF popu-
lations from at least three tumor specimens per treatment group were isolated and
cultured into 100 mm culture dishes (Corning® LifeSciences) in DMEM supple-
mented with 10% (v/v) FBS, 50 μg/mL gentamycin and 1× antibiotic/antimycotic
(15-240-096, Gibco®) in a 5% O2, 5% CO2 incubator at 37 °C. 105 M6 cells were
added to the Petri dish when CAFs derived from the corresponding tumors have
reached 70% conﬂuency and the coculture assays lasted a total of 5 days.
Animals and surgery. All animal procedures were carried out in accordance with
relevant national and international guidelines and according to the animal protocol
approved by the Garvan/St Vincent’s Animal Ethics Committee (Animal ethics
number 11/46). M6-Ctrl or M6-Hh (0.75×106 cells/10 μL) and MDA-MB-231
(1×106 cells/10 μL) transplants were carried out by surgical injection via direct
visualization into the fourth mammary fat pads of pre-pubescent Rag−/− and
NOD-scid IL2rγnull (NSG) mice, respectively.
For limiting dilution studies, single-cell suspensions of viable M6-Ctrl or M6-
Hh tumor cells were prepared as described in the “Tumor dissociation” section.
EpCAM+/GFP+/Lin− tumor cells, isolated by FACS, were transplanted in
appropriate numbers into the fourth mammary fat pad of 3- to 4-week-old
syngeneic Rag−/− mice and aged till ethical endpoint. Extreme limiting dilution
analysis (ELDA16) software was used to calculate the tumor-propagating cell
frequency.
PDX tumor tissues, acquired from the laboratory of A. Welm29 were serially
passaged as 2 mm3 fragments in the cleared fourth mammary fat pads of pre-
pubescent NSG mice according to established protocols29. When tumors became
palpable, they were measured three times weekly in a blinded manner using
electronic calipers to monitor growth kinetics. Tumor volume was calculated using
the formula (π/6) × length × width2. Upon reaching ethical or predeﬁned
experimental endpoints, mice were euthanized and primary tumor and any
associated metastases were collected.
In vivo drug treatment experiments. SMOi GDC-0449 (S1082, Selleckchem) and
NVP-LDE225 (Novartis, Australia) were dissolved in 0.5% methylcellulose, 0.2%
Tween® 80 (Sigma-Aldrich) and 0.5% methylcellulose, 0.5% Tween® 80, respec-
tively, and then delivered by oral gavage (100 mg/kg/bid, GDC-0449; 80 mg/kg/day,
NVP-LDE225). Chemotherapy (Docetaxel, McBeath Australia) was diluted in 5%
dextrose then delivered by intraperitoneal injection (15 mg/kg/week). Tumor-
bearing mice were randomly assigned into respective treatment groups once tumor
volume reached 100 mm3 (n= 7–8 mice per group). Tumor growth was calculated
for each individual tumor by normalizing to the tumor volume at day 0. In short-
term studies examining the molecular and histological impact of Hh pathway
activation and inhibition, mice were treated between 8 and 14 days then eutha-
nized. At euthanasia, primary tumors were harvested and macroscopic metastatic
lesions were scored. For the long-term therapeutic study, mice were treated to
endpoint. Animals were excluded from overall survival analysis if they had to be
sacriﬁced for poor body conditioning, unrelated to tumor size endpoint. Animal
technicians, who were blinded to the experiment treatment groups, independently
monitored the mice.
Next generation sequencing. We isolated by FACS the stromal DAPI−/GFP
−/EPCAM−and epithelial DAPI−/ GFP+/EPCAM+ cell fractions from at least ﬁve
M6-Ctrl and M6-Hh tumor models treated with vehicle (0.5% methylcellulose,
0.2% Tween® 80) or with SMOi. RNA was isolated using the miRNeasy kit (Qia-
gen). For standard input samples, 1 μg of total RNA was used as input to the
TruSeq RNA Sample Preparation Kit v2 (Illumina). The samples were prepared
according to the manufacturer’s instructions, starting with the poly-A pulldown.
The number of PCR cycles was reduced from 15 to 13, to minimize duplications.
The samples were sequenced on the HiSeq2000 using v3 SBS reagents (Ramaciotti
Centre for Genomics, University of New South Wales (UNSW)). Low-input RNA
stromal samples were ﬁrstly ampliﬁed using the Ovation® RNA-Seq System V2 kit
(4 ng of total RNA input; Nugen Integrated Sciences Pty. Ltd.) according to the
manufacturer’s instructions. 1 μg of the cDNA was sheared with Covaris to frag-
ment sizes of ~200 bp. The material was used as input to the TruSeq RNA Sample
Preparation v2 kit, starting at the end-repair step. The number of PCR cycles was
reduced from 15 to 10. All the samples were sequenced on the HiSeq2000 using v3
SBS reagents (Ramaciotti Centre for Genomics, University of New South Wales).
Bioinformatics and computational analysis. Analysis of the RNA-Sequencing
data was conducted on the high-performance computing cluster at the Garvan
Institute following a standard four-step approach, cleaning, aligning, counting, and
differential expression with an additional normalization step. FASTQ ﬁles were
quality checked using FastQC version 0.11.1 (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/) and FastQ Screen version 0.4.4 (http://www.bioinformatics.
babraham.ac.uk/projects/fastq_screen/) then quality ﬁltered using FastqMCF ver-
sion 1.1.2 (https://code.google.com/p/ea-utils/wiki/FastqMcf) to remove low qual-
ity bases and adapter contamination. Filtered reads were then aligned to the mouse
reference genome GRCm38/mm10 using STAR, version 2.4.0d . Feature counting
was performed using HTSeq version 0.5.4p3 . Due to high levels of variation in the
expression data between replicates, the RUV normalization procedure was
implemented69. This aims to remove unwanted variation and produce more reli-
able pair-wise comparisons when calculating differential expression. In this
instance, RUVr with a K of 3 was found to be the most effective method based on
the suggested diagnostics, e.g. plots of P value distributions and PCA. Differential
expression analysis was performed within the RUV analysis using edgeR70.
Single-cell RNA-Sequencing using the Chromium Platform. M6 tumors were
processed into single-cell suspensions as described previously. Sorted live single
epithelial and stromal cells were loaded on a Chromium Single Cell Instrument
(10× Genomics, Pleasanton, CA) to generate single-cell Gel Bead-in-Emulsion
(GEMs). As per the manufacturer’s instructions, approximately ~7000 cells were
loaded per channel for a target of ~4000 cells (10× Genomics). Two biological
replicates were analyzed per sample. Single-cell RNA-Seq libraries were prepared
using the Chromium Single Cell 30 Gel Bead and Library Kit (10× Genomics).
Single-cell sequencing libraries were generated from sorted cells collected in par-
allel on the same Chromium Single Cell Chip and sequenced in multiplexed pairs
to minimize experimental variability and any confounding batch effects. Single-cell
libraries were sequenced using the Illumina NextSeq 500 system using the fol-
lowing parameters: pair-end sequencing with dual indexing, 26 cycles for Read1, 8
cycles for I7 Index Read and 98 cycles for Read2.
The Cell Ranger Single Cell Software v2.0 (10× Genomics) was used to process
raw bcl ﬁles to perform sample demultiplexing, barcode processing and single-cell
3′ gene counting (https://software.10xgenomics.com/single-cell/overview/
welcome). Reads were mapped to the mm10 mouse reference genome. The Cell
Ranger aggregation pipeline was used to normalize the sequencing depths of
multiple datasets (based on the proportion of mapped reads) to recompute a
combined gene−cell barcode matrix.
Downstream ﬁltering and analysis of the raw gene−cell barcode matrix was
performed using the Seurat v2.0 package in R71. The gene−cell barcode matrix was
ﬁltered based on number of genes detected per cell (any cells with less than 500 or
more than 6000 genes per cell were ﬁltered), a total number of unique molecular
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identiﬁers (UMIs) (any cells with UMIs > 50,000 were ﬁltered) and a percentage of
mitochondrial UMI counts (any cells with more than 10% of mitochondrial UMI
counts were ﬁltered). Altogether, in the combined ﬁve datasets, a total of 14,950
cells and 18,487 genes were analyzed. Based on an expression cut-off of 0.0125 and
a dispersion cut-off of 0.5, a total of 2620 variable genes were selected for principal
component analysis (PCA). A total of 91 signiﬁcant principal components
(determined using JackStraw in Seurat, P < 0.05) were used for clustering analysis
and t-SNE projection. The classiﬁcation of cell clusters was inferred using the
following canonical markers: CAFs (Pdpn and Pdgfrb), epithelial cancer cells
(Epcam), endothelial cells (Cd34 and Pecam1), macrophages/monocytes (Ptprc and
Cd68), neutrophils (Ptprc and Csf3r), and natural killer cells (Ptprc and Ncr1).
Differential gene expression analysis in Seurat was performed using the “bimod”
likelihood-ratio test.
Gene set enrichment analysis. Gene-sets used in GSEA were extracted from
version 3.1 and 4.0 of the Broad Institute’s Molecular Signatures Database
(MSigDB) and extended with additional curated gene-sets from literature. All
GSEA analyses were performed using a combined set of the c2, c5 and c6 from
MSigDB plus additional curated sets that we identiﬁed in the literature.
Association of gene signatures with clinical outcome. A stringent mouse gene
signature was derived through differential expression analysis of the stromal
fraction of M6-Hh tumors in comparison to the stroma of M6-Ctrl or M6-Hh
tumors treated with SMOi. The stromal mouse gene signature was then converted
to human genes using NCBI homolog gene list v68 (http://www.ncbi.nlm.nih.gov/
homologene). The converted gene list consists of 146 upregulated genes and 39
downregulated genes in the Hh-activated stromal population (Supplementary
Data 1). The gene list was further assessed for survival analysis using the TCGA
breast invasive carcinoma cohort. The processed TCGA data were downloaded
from cBioPortal72 based on the TCGA study19. The gene signature score was
deﬁned by a weighted average method for each sample in the TCGA cohort.
Survival curves were estimated using the Kaplan−Meier method, with overall
survival used as the outcome metric.
RNA isolation and quantitative RT-PCR experiments. Individual stromal CAFs
and epithelial malignant M6 cancer cells were FACS-isolated as described above.
For each fraction, between 1,000 and 50,000 cells were directly collected into
QIAzol lysis reagent. Low-input RNA samples were then isolated using the miR-
Neasy Micro kit (Qiagen). All the other standard input RNA samples were isolated
using the miRNeasy kit (Qiagen) and reverse transcribed with the Transcriptor
First Strand cDNA Synthesis Kit (Roche Diagnostics). cDNA was synthesized from
0.5 to 2 μg of total RNA and diluted 1:10 before any further quantitative RT-PCR
(qRT-PCR) analysis.
qRT-PCR experiments were performed using either the Roche Universal Probe
Library System on a Roche LightCycler480® (Roche LifeScience) or the TaqMan
Gene Expression Assay (Applied Biosystems/Life Technologies) on an ABI Prism®
7900 HT Sequence Detection System (Perkin-Elmer Applied Biosystems). Primers,
probes, and programs used for qRT-PCR analysis are listed in Supplementary
Table 4. Relative mRNA expression levels were normalized to β-actin, GAPDH, or
HPRT and quantiﬁcation was performed using the comparative CT method
described by Livak and Schmittgen73.
Histological assays and analysis. Tissues were ﬁxed in 10% neutral buffered
formalin at 4 °C overnight then processed for parafﬁn embedding. For histological
analysis, 4 μm tissue sections were stained with hematoxylin and eosin using
standard methods. Immunohistochemical, immunoﬂuorescence, and picrosirius
red staining were performed on parafﬁn-embedded tissue sections using standard
protocols. Full details of each antibody used and their relative staining protocols for
immunochemistry are described in Supplementary Table 3.
Histological analysis of the proliferative marker phospho-histone H3, ALDH-1,
and the progenitor cell marker CK6 were carried out by digitizing entire images
using the Aperio CS2 digital pathology slide scanner (Leica Biosystem) at ×20
magniﬁcation. Cells that stained positively for phospho-Histone H3, ALDH-1, or
CK6 within a distance of 200 μm from CAFs at the tumor−stromal interface were
then counted and averaged over at least ﬁve ﬁelds using the Aperio Imagescope
software (Leica Biosystem). The limit of 200 μm reﬂects the well-established
diffusional distance for Hh ligand in mammalian models74. Picrosirius red stain
was analyzed as previously described75. Two specialist breast pathologists, who
were blinded to the experiment treatment groups, independently scored the
remaining IHC stains. Areas of necrosis were excluded for all analyses. The number
of CD45+ cells in the peritumoral stroma and the number of CD31+ blood vessels
were estimated and averaged over ﬁve high power ﬁelds (×40 magniﬁcation).
Alpha-SMA was scored as the percentage of myoﬁbroblabts in the tumor stroma at
the whole tumor level. Tumor vs. stromal ratio was estimated on H&E sections.
For immunoﬂuorescence staining, formalin-ﬁxed parafﬁn-embedded (FFPE)
sections on Superfrost+ glass slides (Thermo) were dewaxed and rehydrated, and
antigen retrieval was performed by boiling for 12 min in 10 mM citrate buffer (pH
6.0) or 10 mM Tris-Cl (pH 9.0) in a pressure cooker (Supplementary Table 3).
Following blocking with 10% goat serum, sections were incubated with the primary
antibodies p(Tyr397)-FAK, CK6, ALDH1, E-cadherin at 4 °C for 18 h, washed in
PBS and incubated with the appropriate secondary antibodies for 1 h. After
washing in PBS, sections were incubated with 0.2 µg/mL DAPI in PBS for 5 min to
label nuclei and mounted. Confocal ﬂuorescence images were captured using an
LSM 700 confocal scanning system (Carl Zeiss AV), with Zen 2011 (Black Edition)
version 8.1.5.484 software. Images were processed using ImageJ (National Institutes
of Health, Bethesda MD, USA) as previously described42. Two cell biologists from
separate institutes, who were blinded to the treatment groups, independently
scored the IF stains for CK6, ALDH1, and phospho-FAK.
Microscopy analyses of collagen deposition and organization. Formalin-ﬁxed,
parafﬁn-embedded sections stained with hematoxylin and eosin and mounted in
DPX (Sigma) were imaged using a ×20 1.0 NA objective on an upright ﬁxed-stage
two-photon laser scanning microscope system (Zeiss). The excitation source was a
Ti:Sapphire femto-second laser cavity (Newport Mai Tai), coupled into an LSM
710 scan module. An excitation wavelength of 890 nm was used to collect SHG
signal (435 ± 20 nm) from collagen. Maximum collagen coverage values derived
from SHG signal (by depth (line graph) and at peak value (histogram inset)) was
used as a measure of collagen abundance and density. Signal was acquired from
three separate areas measuring 320 × 320 μm2 across each sample. Bright-ﬁeld
transmission images were co-acquired with SHG data.
ImageJ was used to calculate percentage area covered by SHG signal per image,
after conversion to a binary image based upon a single manually determined
threshold value applied across all images as previously described41. Results were
expressed as medians, ranges, and quartiles across all datasets.
Stromal collagen ﬁber organization and crosslinking were assessed using
GLCM24 analysis to characterize the texture of a sample and determine the
correlation of the SHG signal within the matrix. The correlation plots represent the
similarity in signal strength between pixels. A slower decay shows a more organized
and correlated network of collagen ﬁbers than in samples with a faster decay.
GLCM analysis was performed in ImageJ.
Orientation analysis was carried out as previously described23. Brieﬂy, ﬁber
orientation analysis was performed on SHG images using an in-house ImageJ
macro where structure tensors were derived from the local orientation and
isotropic properties of pixels that make up collagen ﬁbrils. Within each input
image, these tensors were evaluated for each pixel by computing the continuous
spatial derivatives in the x and y dimensions using a cubic B-spline interpolation.
From this, the local predominant orientation was obtained. The peak alignment
(measured in degrees) of ﬁbers was then determined, and the frequency of ﬁber
alignment calculated.
Alginate-Collagen I Inter-Penetrating Network hydrogels. Alginate-Collagen I
Inter-Penetrating Network (IPNs) hydrogels were generated from 1% sodium
alginate mixed with either 20, 5 or 0% rat tail collagen I, plus 1% Matrigel. A
standard guide describing cell encapsulation in alginate is available from ASTM
International (ASTM F2315–11). Well-characterized alginates with high purity and
G-block composition were used to prepare hydrogels with consistent mechanical
properties for cell encapsulation. M6-Ctrl and M6-Hh single cells were encapsu-
lated in 400 μm diameter beads before transferring to normal growth media.
Colony-forming ability was assessed at days 5, 8, and 12.
Tumorsphere assays. Low passage M6 cells grown to 70–80% conﬂuency as
adherent monolayer were trypsinized, quenched in normal culture media, washed
three times with large volumes of calcium-magnesium-free PBS then passed
through a 40 μm cell strainer to obtain a single-cell suspension. Cell number was
determined using the Countess™ Automated Cell Counter (Invitrogen) then seeded
in sphere-promoting culture at a density of 2.5×103 cells/mL in ultra low-adherent
six-well plates (Corning® LifeSciences). Cells were grown at 37 °C in a 5% CO2
incubator. Primary sphere formation efﬁciency was determined after 5 days.
Spheres larger than 40 μm were counted manually using a light microscope
and automatically using the IncuCyte ZOOM® Live Cell System (Essen BioScience).
Primary spheres were then collected by gentle centrifugation and washed
with calcium-magnesium-free PBS prior to dissociation into single-cell
suspension. Cell number was determined as above then seeded in triplicate at a
density of 5×102 cells/mL in ultra low-adherent six-well plates. Secondary sphere
formation efﬁciency was determined after 8 days. Sphere media was composed of
DMEM/F12, 1% methylcellulose, 1× B27 supplement (17504-044, Invitrogen), and
4 μg/mL sodium heparin (H3149-50KU, Sigma-Aldrich). Tumorspheres were
treated with 150 ng/mL recombinant FGF5 (237-F5-050, R&D Systems) and/or
500 nM FGFR inhibitor, NVP-BGJ 398 (S2183, Selleckchem). Sphere formation
efﬁciency was calculated using the following formula: (Number of tumorspheres
larger than 40 μm / Number of single cells seeded) × 100%.
Patients. Patients in this study were enrolled in the GEICAM/2012-12 (EDALINE)
clinical trial (ClinicalTrials.gov Identiﬁer: NCT02027376); a single-arm, open-label,
phase I, 3+ 3 dose escalation study in which patients with TNBC were treated with
the SMOi Sonidegib (LDE-225) in combination with docetaxel to determine the
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MTD and the Recommended Phase II Dose (RP2D), as the primary objective.
Written informed consent was obtained from all patients and documented before
performing any protocol-speciﬁc procedure. The study was conducted in accor-
dance with the International Conference on Harmonization Good Clinical Practice
Guidelines (ICH GCP), the Declaration of Helsinki and applicable local regulatory
requirements and laws. The protocol was approved by the Institutional Review
Board and the Ethics Committee of all the participating sites (Hospital General
Universitario Gregorio Marañón, Hospital Universitario Clínico San Carlos,
Complejo Hospitalario Universitario A Coruña, Hospital Universitario Virgen del
Rocío, Hospital Universitario Virgen de la Victoria), according to the requirements
of the Spanish regulations (GEICAM/2012-12; clinicaltrials.gov identiﬁer:
NCT02027376). Eligible patients, with no more than three previous lines of che-
motherapy for metastatic disease were treated with 21-day cycles of intravenous
docetaxel 75 mg/m2 on day 1 and oral Sonidegib administered at increasing doses
of 400, 600, and 800 mg once daily (QD), until radiographic or symptomatic
progression, unacceptable toxicity or withdrawal of the informed consent, which-
ever occurred ﬁrst. All patients at each dose level completed at least two treatment
cycles before being enrolled to the next Sonidegib dose level. Twelve patients were
enrolled into the study and were treated as described above.
Clinical markers of therapeutic activity. The expression of Hedgehog ligand
(HH) and GLI1 were examined by immunohistochemistry (IHC) from archived
FFPE pretreatment primary breast tumors from patients enrolled in the EDALINE
clinical trial. Pathologists, who were blinded to clinical parameters, carried out
biomarker analysis. Two specialist breast pathologists independently calculated the
Histo-score (Hscore) based on the percentage of stained cells (HH and GLI1
expression) and staining intensity on a predetermined scale (0: no staining to 3:
strong), in the tumor epithelial cells (HH) and the tumor stroma (GLI1). Pre-
deﬁned cut-offs for high/low biomarker expression were established based on
standard criteria (median Hscore for HH in tumor cells and intensity staining for
GLI1 in the stroma).
We deﬁned an HPAS predictive for clinical response to sonidegib (LDE-225) in
combination with docetaxel as cases with both high HH expression in the tumor
epithelium (HH Hscore > 150) and intense GLI1 expression in the tumor stroma.
Statistical analysis. All statistical analyses were performed using GraphPad Prism
6.0c software (GraphPad Software). For all in vitro experiments, three or six
technical replicates were analyzed for each experiment, and results are presented as
the mean ± s.e.m. of three biological replicates. Quantitative analyses were carried
out using unpaired two-tailed Student’s t test with equal standard deviation after
conﬁrming that the data met appropriate assumptions (normality, homogenous
variance, and independent sampling). Seven to ten mice per treatment group were
used for all in vivo experiments with SMOi treatment. Five mice per treatment
group were utilized for RNA-Seq. For all RT-qPCR experiments, three technical
replicates were analyzed for each experiment, and results are presented as the
mean ± s.e.m. of three biological replicates. Subsequent statistical analyses of
in vivo experiments were performed with either unpaired two-sided Student’s t
tests or the Fisher’s exact test. Survival analysis was performed using the Log-rank
(Mantel−Cox) test. A P value < 0.05 was considered statistically signiﬁcant. *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Estimation of variation within each
group was determined by s.e.m. Sample size estimation was initially chosen by
using power calculations for guidance (http://biomath.info/power/ttest.htm). Effect
sizes were estimated at 30% for single agent arms, based on earlier data with single
agent docetaxel and SMO inhibitors. With alpha= 0.05 and power= 0.9 and
allowing for attrition of ~1 mouse/group, ≥7 mice per group were needed for all
preclinical studies. For the Phase I clinical trial EDALINE, descriptive analysis on
demographic and clinicopathological characteristics (age, visceral disease, number
of involved sites, prior treatment, histologic tumor grade and Ki67), Hh biomarkers
expression (HH and GLI1) and efﬁcacy data to the combined therapy sonidegib
with docetaxel were performed. The Chi-square test of Independence was assessed
to examine the association between epithelial HH and stromal GLI1 expression and
efﬁcacy endpoints: best tumor response (complete or partial response, stable dis-
ease, progression disease, and Time to Progression (TTP)). TTP was deﬁned as the
time from treatment commencement until objective tumor progression (does not
include deaths). Progression-free survival (PFS) was explored using Kaplan−Meier
survival analysis. PFS was deﬁned as the time from treatment commencement until
disease progression or death. For mouse and clinical studies, specialists were
blinded to the experiment treatment groups.
Data availability. All relevant data are available from the authors. All RNA-
Sequencing ﬁles that support the ﬁndings of this study have been deposited in GEO
with the accession code PRJNA369574. The RNA-Seq pipeline and the analysis
scripts can be found on the respective websites: https://github.com/elswob/rna-seq-
pipe and https://github.com/elswob/Hh.
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